PNP Inhibitor Combination Therapy for Hematologic Cancer Resistance
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatments, particularly for hematologic cancers like CLL and ALL, face challenges due to drug resistance and the limitations of existing chemotherapeutic agents, which often result in recurrence or death, necessitating more effective therapies.
Innovation Solution
The administration of a purine nucleoside phosphorylase (PNP) inhibitor, such as Forodesine, in combination with an alkylating agent or an anti-CD20 agent, such as Bendamustine or Rituximab, to induce cytotoxicity and apoptosis in cancer cells, bypassing resistance mechanisms and targeting specific pathways like the ATM/p53 pathway.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional chemotherapeutic agents are used to treat hematologic cancers, then initial treatment may be effective, but drug resistance develops leading to treatment failure
Solution Approach 1:
The patent combines PNP inhibitor (Forodesine) with alkylating agents or anti-CD20 agents to create a multi-modal treatment approach. This combination targets cancer cells through multiple mechanisms simultaneously, preventing the development of resistance that occurs with single-agent therapy.
Solution Approach 2:
The invention changes the therapeutic parameter by introducing a novel mechanism of action (PNP inhibition) that is independent of the traditional chemotherapy pathways. This allows treatment of cancers that have developed resistance to conventional agents by targeting a different biological pathway.
2Reliability
If surgery is used to remove tumors, then localized tumors can be effectively treated, but disseminated conditions like leukemia cannot be treated
Solution Approach 1:
The PNP inhibitor combined with alkylating or anti-CD20 agents provides a universal treatment approach that can be applied to various hematologic cancers including CLL and ALL. The regimen addresses both localized and disseminated disease through systemic administration, making it versatile across different clinical presentations.
3Reliability
If radiation therapy is used to treat cancer, then localized tumor control is achieved, but acute and irreversible side effects occur
Solution Approach 1:
The PNP inhibitor acts as an intermediary that enhances the effectiveness of alkylating agents or anti-CD20 agents while allowing for potentially lower doses of these agents. This mediation may reduce the harmful effects associated with high-dose chemotherapy while maintaining treatment efficacy.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This combination therapy demonstrates a synergistic effect in inducing significant cell death in CLL cells, overcoming drug resistance and achieving high cytotoxicity rates, even in cases resistant to conventional chemotherapeutics, with Forodesine showing a novel mechanism of action independent of p53 status.
Implementation Method 1
administering to the subject an effective amount of a purine nucleoside phosphorylase (PNP) inhibitor
Implementation Method 2
administering to the subject an effective amount of an alkylating agent
Data Source
AI summary
The present application relates to treatment of hematologic cancers, which treatments can include, e.g., administration of a purine nucleoside phosphorylase (PNP) inhibitor, an alkylating agent and/or an anti-CD20 agent, and related compositions and kits.